| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1651 |
| Trial ID | NCT02926833 |
| Disease | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | YesCAR-Ta|Axicabtagene Ciloleucel|axi-cel |
| Co-treatment | Atezolizumab |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
| Year | 2016 |
| Country | United States |
| Company sponsor | Kite, A Gilead Company |
| Other ID(s) | KTE-C19-106 |
| Cohort 1 | |||||||||
|
|||||||||